COVID-19 rebound after Paxlovid treatment during Omicron BA.5 vs BA.2.12.1 subvariant predominance period | medRxiv

Data Availability

All data produced in the present work are contained in the manuscript

Data Availability

All data produced in the present work are contained in the manuscript

View the discussion thread.

Posted August 06, 2022.

Supplementary Material

Subject Area

Infectious Diseases (except HIV/AIDS)

Subject Areas

All Articles

Addiction Medicine (399)
Allergy and Immunology (708)
Anesthesia (200)
Cardiovascular Medicine (2913)
Dentistry and Oral Medicine (332)
Dermatology (249)
Emergency Medicine (438)
Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1030)
Epidemiology (12699)
Forensic Medicine (12)
Gastroenterology (825)
Genetic and Genomic Medicine (4557)
Geriatric Medicine (414)
Health Economics (724)
Health Informatics (2908)
Health Policy (1068)
Health Systems and Quality Improvement (1071)
Hematology (385)
HIV/AIDS (921)
Infectious Diseases (except HIV/AIDS) (14075)
Intensive Care and Critical Care Medicine (842)
Medical Education (422)
Medical Ethics (115)
Nephrology (466)
Neurology (4324)
Nursing (233)
Nutrition (634)
Obstetrics and Gynecology (799)
Occupational and Environmental Health (734)
Oncology (2256)
Ophthalmology (642)
Orthopedics (258)
Otolaryngology (324)
Pain Medicine (277)
Palliative Medicine (83)
Pathology (496)
Pediatrics (1196)
Pharmacology and Therapeutics (502)
Primary Care Research (493)
Psychiatry and Clinical Psychology (3728)
Public and Global Health (6909)
Radiology and Imaging (1522)
Rehabilitation Medicine and Physical Therapy (892)
Respiratory Medicine (914)
Rheumatology (435)
Sexual and Reproductive Health (443)
Sports Medicine (381)
Surgery (483)
Toxicology (60)
Transplantation (209)
Urology (178)